Cargando…

Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment

Introduction: An infection by COVID-19 triggers a dangerous cytokine storm, so tocilizumab has been introduced in Italy as an agent blocking the cytokine storm. This paper aims to describe the one-year survival of ICU patients treated with tocilizumab. Methods: This observational study enrolled all...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melegari, Gabriele, Giuliani, Enrico, Dallai, Chiara, Veronesi, Lucia, Bertellini, Elisabetta, Osmenaj, Suela, Barbieri, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622280/ https://www.ncbi.nlm.nih.gov/pubmed/34834586 http://dx.doi.org/10.3390/jpm11111234

Ejemplares similares

COVID-19 Biomarkers for Critically Ill Patients: A Compendium for the Physician
por: Arturi, Federica, et al.
Publicado: (2023)

Point-of-care pancreatic stone protein measurement in critically ill COVID-19 patients
por: Melegari, Gabriele, et al.
Publicado: (2023)

Novel coronavirus (2019-nCov): do you have enough intensive care units?
por: Melegari, G., et al.
Publicado: (2020)

Novel coronavirus (2019-nCov): do you have enough intensive care units?
por: Melegari, G., et al.
Publicado: (2020)

COVID-19: Relative Risk of Non-Vaccinated to Vaccinated Individuals
por: Barbieri, Davide, et al.
Publicado: (2022)

Dynamic Angiopoietin-2 Serum Level as Endothelial Damage Marker and Potential Therapeutic Target
por: Melegari, Gabriele, et al.
Publicado: (2022)

Description, Organization, and Individual Postgraduate Perspectives of One Italian School of Anesthesia and Intensive Care
por: Villani, Matteo, et al.
Publicado: (2022)

Permissive Apnea in COVID-19 Tracheostomy: Alternative Health Worker Safe Procedure in Intensive Care Unit
por: Marudi, Andrea, et al.
Publicado: (2021)

Mild to Severe Neurological Manifestations of COVID-19: Cases Reports
por: Melegari, Gabriele, et al.
Publicado: (2021)

One year later: The case of tocilizumab in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19
por: Villa, Erica, et al.
Publicado: (2021)

Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19
por: Monti, Giulia, et al.
Publicado: (2020)

Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care
por: Taramasso, Lucia, et al.
Publicado: (2021)

Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation
por: Menzella, Francesco, et al.
Publicado: (2020)

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
por: Mikulska, Malgorzata, et al.
Publicado: (2020)

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes
por: Al-Baadani, Abeer, et al.
Publicado: (2021)

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
por: Livermore, P, et al.
Publicado: (2008)

Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One
por: Kow, Chia Siang, et al.
Publicado: (2021)

Education in anesthesia: three years of online logbook implementation in an Italian school
por: Barbieri, Alberto, et al.
Publicado: (2015)

Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
por: Talotta, Rossella, et al.
Publicado: (2018)

Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report
por: Burlo, Francesca, et al.
Publicado: (2023)

Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab
por: Morrison, Austin R., et al.
Publicado: (2020)

Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia
por: Gokhale, Yojana, et al.
Publicado: (2020)

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
por: Klopfenstein, T., et al.
Publicado: (2020)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

How Artificial Intelligence and New Technologies Can Help the Management of the COVID-19 Pandemic
por: Barbieri, Davide, et al.
Publicado: (2021)

Tocilizumab and COVID-19
por: Chaudhry, Dhruva, et al.
Publicado: (2020)

Ibuprofen timing for hand surgery in ambulatory care
por: Giuliani, Enrico, et al.
Publicado: (2015)

Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients
por: Marfella, R., et al.
Publicado: (2020)

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
por: Biran, Noa, et al.
Publicado: (2020)

Fatigue in intensive care survivors one year after discharge
por: Spadaro, Savino, et al.
Publicado: (2016)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

One-year survival of patients admitted to the neurological intensive care unit
por: Puntis, M, et al.
Publicado: (2007)

[(18)F]FDG PET/CT in Patients Affected by SARS-CoV-2 and Lymphoproliferative Disorders and Treated with Tocilizumab
por: Signore, Alberto, et al.
Publicado: (2022)

Tocilizumab: Neutropenia: case report
Publicado: (2020)

Günstige Effekte von Tocilizumab
por: Diener, Hans-Christoph
Publicado: (2020)

Papulopustular Rash Due to Tocilizumab
por: Kohro-Kawata, Junko, et al.
Publicado: (2019)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Tocilizumab ohne überzeugende Wirkung
por: Diener, Hans-Christoph
Publicado: (2021)

Cases of pancreatitis reported with tocilizumab
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_astfdifvjqqedh5dggeae077p9